Patents by Inventor Vu Hong

Vu Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
    Patent number: 12721847
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: September 1, 2026
    Assignee: Disc Medicine, Inc.
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20260232656
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: July 26, 2023
    Publication date: August 13, 2026
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA
    Publication number: 20260027107
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating polycythemia, and related syndromes thereof.
    Type: Application
    Filed: March 11, 2022
    Publication date: January 29, 2026
    Inventors: John Quisel, William Jacob Savage, Maria Gabriela Beconi, Vu Hong, Min Wu, Yi Xiang, Pavan Reddy
  • COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20250302823
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating a hepatic porphyria, and related syndromes thereof.
    Type: Application
    Filed: May 30, 2023
    Publication date: October 2, 2025
    Inventors: Maria Gabriela Beconi, Min Wu, Vu Hong
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20250262204
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: November 8, 2024
    Publication date: August 21, 2025
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA
    Publication number: 20250248995
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating polycythemia, and related syndromes thereof.
    Type: Application
    Filed: October 23, 2024
    Publication date: August 7, 2025
    Inventors: John Quisel, William Jacob Savage, Maria Gabriela Beconi, Vu Hong, Min Wu, Yi Xiang, Pavan Reddy
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20250228827
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: March 12, 2025
    Publication date: July 17, 2025
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • AMINE BASED MATRIPTASE 2 INHIBITORS AND USES THEREOF
    Publication number: 20240400553
    Abstract: The present disclosure provides amine based compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.
    Type: Application
    Filed: April 11, 2024
    Publication date: December 5, 2024
    Applicant: Disc Medicine, Inc.
    Inventors: Srikanth Venkatraman, Vu Hong, Venkateshwar Rao Gummadi, Bharathi Raja Ainan, Brahma Reddy Vare, Sharad Chandrakant Deshmukh
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN
    Publication number: 20240390362
    Abstract: The present embodiments are directed to methods of using a crystalline form (such as form A, B, or C, or a methylparaben cocrystal form) or an amorphous form of Bitopertin, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: May 26, 2022
    Publication date: November 28, 2024
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20240366574
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT 1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 7, 2024
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • PEPTIDOMIMETIC MATRIPTASE 2 INHIBITORS AND USES THEREOF
    Publication number: 20240317801
    Abstract: The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for modulating the activity of Matriptase 2 (“Mat-2”), or a mutant thereof. The present disclosure also provides pharmaceutically acceptable compositions comprising compounds of the present disclosure and methods of using said compositions in the treatment of various disease and disorders related to Mat-2.
    Type: Application
    Filed: December 16, 2021
    Publication date: September 26, 2024
    Applicant: Disc Medicine, Inc.
    Inventors: Srikanth Venkatraman, Vu Hong, Savina Malancona, Christian Montalbetti, Paola Fezzardi
  • COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA
    Publication number: 20240269132
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating polycythemia, and related syndromes thereof.
    Type: Application
    Filed: March 5, 2024
    Publication date: August 15, 2024
    Inventors: John Quisel, William Jacob Savage, Maria Gabriela Beconi, Vu Hong, Min Wu, Yi Xiang, Pavan Reddy
  • Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
    Patent number: 11813257
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: November 14, 2023
    Assignee: Disc Medicine, Inc.
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE
    Publication number: 20230348450
    Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 2, 2023
    Inventors: Kunal Desai, Zhong Fang, Kevin Guertin, Vu Hong, John Ziqi Jiang, Sungtaek Lim, Mark Munson
  • COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE
    Publication number: 20230348454
    Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 2, 2023
    Inventors: Kunal Desai, Zhong Fang, Kevin Guertin, Vu Hong, John Ziqi Jiang, Sungtaek Lim, Jinyu Liu, Mark Munson
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20210283129
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 16, 2021
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong